CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-17 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,254,179 |
| 2024-04-17 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −23,124 | $7.58 | $175K | 1,231,055 |
| 2024-04-17 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 810,135 | ||
| 2024-04-16 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $7.66 | $88K | 7,229,861 |
| 2024-04-16 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,241,679 |
| 2024-04-16 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $7.67 | $192K | 1,216,679 |
| 2024-04-16 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 847,635 | ||
| 2024-04-04 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $9.02 | $361K | 938,524 |
| 2024-04-04 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +25,000 | 25,000 | ||
| 2024-04-04 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −25,000 | $9.02 | $226K | 0 |
| 2024-04-04 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −25,000 | 486,000 | ||
| 2024-04-03 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −25,000 | 1,018,524 | ||
| 2024-04-03 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $8.84 | $354K | 978,524 |
| 2024-04-03 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +25,000 | 25,000 | ||
| 2024-04-03 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −25,000 | $8.84 | $221K | 0 |
| 2024-04-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −25,000 | 67,875 | ||
| 2024-04-02 | Borgeson Blake Director | Sale 10b5-1 | −11,447 | $8.82 | $101K | 7,241,308 |
| 2024-04-01 | Li Dean Y Director | Grant or award | +1,267 | 59,089 | ||
| 2024-04-01 | CHAVEZ R. MARTIN Director | Grant or award | +2,001 | 60,078 | ||
| 2024-04-01 | Dar Zavain Director | Grant or award | +1,467 | 89,056 |
Page 21 of 41 · 805 trades